Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective
Molecular & Cellular Proteomics · 2023
DOI: 10.1016/j.mcpro.2023.100578 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular & Cellular Proteomics, 2023. Verfasst von Liujia Qian und 3 weiteren Autor:innen. Beteiligte Einrichtung: iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences…. Hauptthemen laut MEDLINE: Neoplasms, Glandular and Epithelial, Ovarian Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Increasing proteomic studies focused on epithelial ovarian cancer (EOC) have attempted to identify early disease biomarkers, establish molecular stratification, and discover novel druggable targets. Here we review these recent studies from a clinical perspective. Multiple blood proteins have been used clinically as diagnostic markers. The ROMA test integrates CA125 and HE4, while the OVA1 and OVA2 tests analyze multiple proteins identified by proteomics. Targeted proteomics has been widely used to identify and validate potential diagnostic biomarkers in EOCs, but none has yet been approved for clinical adoption. Discovery of proteomic characterization of bulk EOC tissue specimens has uncovered a large number of dysregulated proteins, proposed new stratification schemes, and revealed novel targets of therapeutic potential. A major hurdle facing clinical translation of these stratification schemes based on bulk proteomic profiling is intra-tumor heterogeneity, namely that single tumor specimens may harbor molecular features of multiple subtypes. We reviewed over 2500 interventional clinical trials of ovarian cancers since 1990 and cataloged 22 types of interventions adopted in these trials. Among 1418 clinical trials which have been completed or are not recruiting new patients, about 50% investigated chemotherapies. Thirty-seven clinical trials are at phase 3 or 4, of which 12 focus on PARP, 10 on VEGFR, 9 on conventional anti-cancer agents, and the remaining on sex hormones, MEK1/2, PD-L1, ERBB, and FRα. Although none of the foregoing therapeutic targets were discovered by proteomics, newer targets discovered by proteomics, including HSP90 and cancer/testis antigens, are being tested also in clinical trials. To accelerate the translation of proteomic findings to clinical practice, future studies need to be designed and executed to the stringent standards of practice-changing clinical trials. We anticipate that the rapidly evolving technology of spatial and single-cell proteomics will deconvolute the intra-tumor heterogeneity of EOCs, further facilitating their precise stratification and superior treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China; Institute of Basic M…
Förderung
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research
Zitieren
APA
Qian, L., Sun, R., Xue, Z., & Guo, T. (2023). Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2023.100578
Vancouver
Qian L, Sun R, Xue Z, Guo T. Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective. Molecular & Cellular Proteomics. 2023. doi:10.1016/j.mcpro.2023.100578
BibTeX
@article{Qian2023,
author = {Qian, Liujia and Sun, Rui and Xue, Zhangzhi and Guo, Tiannan},
title = {Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective},
journal = {Molecular & Cellular Proteomics},
year = {2023},
doi = {10.1016/j.mcpro.2023.100578}
}
EUVIMED